EXCELLENT登记研究:使用EMBOTRAP装置进行血管内卒中治疗的前瞻性、多中心、全球登记研究
EXCELLENT是一项前瞻性全球登记研究,在34个中心纳入997例以EMBOTRAP作为一线机械取栓装置的急性缺血性卒中患者,评估真实世界有效性与取出血栓成分。首次通过mTICI≥2b率为64.5%,最终mTICI≥2b率为94.5%,90天mRS 0~2或≤基线为46.8%,90天死亡率为19.1%。
要点
- 首次通过mTICI≥2b率64.5%,最终mTICI≥2b率94.5%。
- 90天mRS 0~2或≤基线者占46.8%,90天死亡率19.1%。
- 任何取栓操作均未取出栓块者基线影像高密度征或磁敏感血管征比例较低(58.9% vs 74.7%,P<0.001)。
核心结论
- EXCELLENT登记研究反映了机械取栓的真实世界实践,并揭示了当前技术可有效取出的栓块范围。
- 这是首份详细描述机械取栓操作未能取出任何栓块材料患者特征的报告。
- 尽管无法对不可取出栓块进行组织学评估,结果支持无栓块取出可能与提示栓块红细胞含量较低的影像学表现相关的观点。
研究设计与样本
- EXCELLENT为前瞻性、全球登记研究,纳入以EMBOTRAP作为一线机械取栓装置治疗的急性缺血性卒中患者。
- 研究于2018年9月至2021年3月在34个中心开展,其中25个中心提供栓块。
- 采用核心影像与中心组织学实验室(对临床数据设盲)、独立90天改良Rankin量表评估及临床事件委员会。
- 筛查3799例患者后,共纳入997例受试者(平均年龄70.0±14.2岁;女性51.8%;非白人19.7%)。
主要发现
- 首次通过mTICI≥2b率为64.5%(623/966),首次通过mTICI≥2c率为39.1%(378/966),最终mTICI≥2b率为94.5%(931/985)。
- 427/912(46.8%)例患者达到90天改良Rankin量表0~2分或≤基线。
- 栓塞至新供血区发生率为0.2%(2/984),24小时症状性颅内出血发生率为1.6%(16/997)。
- 90天死亡率为19.1%(175/918);至90天装置和/或操作相关严重不良事件发生率为5.9%(54/912)。
- 取出血栓的平均红细胞百分比为45.62±21.372;在首次通过即达mTICI≥2b的患者中,红细胞贫乏(<25%)与红细胞丰富(>75%)栓块分别占15.7%(52/331)与9.7%(32/331)。
关键数值与推荐
- 首次通过mTICI≥2b定义为623/966(64.5%),首次通过mTICI≥2c定义为378/966(39.1%)。
- 最终mTICI≥2b定义为931/985(94.5%)。
- 良好功能结局定义为90天改良Rankin量表0~2分或≤基线,为427/912(46.8%)。
- 任何操作均未取出栓块者基线影像高密度征或磁敏感血管征比例低于有栓块取出者(58.9% vs 74.7%,P<0.001)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 无法对不可取出栓块进行组织学评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The EXCELLENT registry aimed to evaluate the effectiveness of the EMBOTRAP Revascularization Device in an all-comer population in a real-world setting, with a focus on the composition of retrieved clots. METHODS: EXCELLENT is a prospective, global registry of patients with acute ischemic stroke treated with EMBOTRAP as the first-line mechanical thrombectomy device conducted at 34 sites (25 sites contributing clot) from September 2018 to March 2021, utilizing core imaging and central histology laboratories blinded to clinical data, independent 90-day modified Rankin Scale assessment and Clinical Events Committee. RESULTS: After screening 3799 patients, a total of 997 subjects (mean age, 70.0±14.2 years; 51.8% women; 19.7% non-White) were included. The first-pass modified Treatment in Cerebral Infarction (mTICI) ≥2b rate was 64.5% (623/966), first-pass mTICI ≥2c was 39.1% (378/966), and final mTICI ≥2b was 94.5% (931/985). A total of 427/912 (46.8%) patients achieved a 90-day modified Rankin Scale of 0 to 2 or ≤baseline. Embolization to a new territory occurred in 0.2% (2/984), and symptomatic intracranial hemorrhage at 24 hours in 1.6% (16/997). The 90-day mortality was 19.1% (175/918). Device- and/or procedure-related serious adverse events occurred in 5.9% (54/912) through 90 days. The mean RBC percentage of retrieved clots was 45.62±21.372. Among patients who achieved mTICI ≥2b with the first pass, 15.7% (52/331) and 9.7% (32/331), respectively, had RBC-poor (<25%) and RBC-rich (>75%) clots. Patients with no clot retrieved in any procedural pass had a lower percentage of hyperdense or susceptibility vessel sign on baseline imaging (58.9% versus 74.7%; P<0.001), pointing to a potential preprocedure indicator of challenging clot. CONCLUSIONS: The EXCELLENT registry informs real-world practices in mechanical thrombectomy and sheds light on the range of clots effectively retrieved by current technology. This is the first report of detailed patient characteristics where mechanical thrombectomy maneuvers failed to remove any clot material. Although the composition of nonretrievable clots cannot be assessed histologically, the results support the notion that no retrieval may be correlated with imaging findings suggesting clots lower in RBC. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT03685578.
引用
- Nogueira RG, Andersson T, Haussen DC, et al. EXCELLENT Registry: A Prospective, Multicenter, Global Registry of Endovascular Stroke Treatment With the EMBOTRAP Device. Stroke. 2024. PMID: 39559856. doi:10.1161/STROKEAHA.124.047324
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。